Vaccination against Rubella
There are a number of rubella vaccines available, either as single antigen vaccines or
combined with either measles vaccine (MR), mumps vaccine or measles and mumps vaccine
(MMR). Most currently licensed vaccines are based on the live, attenuated RA 27/3 strain
of rubella virus, propagated in human diploid cells. The RA 27/3 vaccine is highly stable
at 700 C. When stored at 40 C, its potency is maintained for
at least 5 years. The vaccine should be stored at 20 C 80 C
and protected from light. And the vaccine is administered by subcutaneous route.
In the light of the proven efficacy and safety of the RA 27/3 based rubella vaccine,
WHO recommends its use in all countries where control or elimination of CRS is considered
a public health priority. Current efforts in the global measles control should be used as
an opportunity to pursue control of rubella through the use of MR and MMR vaccines.
Although the global burden of CRS has been sufficiently characterised to justify the
advocating for its control and prevention, further multi-country studies are going on to
refine estimates at national and regional levels, particularly in developing countries. At
the same time integrated measles and rubella surveillance as well as integrated measles
and rubella laboratory networks are being set up.
Other sites and important links